Eupraxia Pharmaceuticals Inc. Common Stock Total Liabilities
Eupraxia Pharmaceuticals Inc. Common Stock total liabilities. Based on the latest financial reports, Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) has total liabilities worth $5.43 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Eupraxia Pharmaceuticals Inc. Common Sto (EPRX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Eupraxia Pharmaceuticals Inc. Common Stock (2017–2024)
Total liabilities of Eupraxia Pharmaceuticals Inc. Common Stock from 2017 to 2024. This chart illustrates how Eupraxia Pharmaceuticals Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Eupraxia Pharmaceuticals Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Eupraxia Pharmaceuticals Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shandong Xinjufeng Technology Packaging Co. Ltd. A
SHE:301296
|
China | CN¥3.38 Billion |
|
VIP Industries Limited
NSE:VIPIND
|
India | Rs12.58 Billion |
|
Jiangsu Flag Chemical Industry Co Ltd
SHE:300575
|
China | CN¥2.81 Billion |
|
Sanyou Corporation Limited
SHE:300932
|
China | CN¥1.79 Billion |
|
Viking Tech
TWO:3624
|
Taiwan | NT$949.58 Million |
|
North American Financial 15
TO:FFN
|
Canada | CA$588.15 Million |
|
K-Bro Linen Inc.
TO:KBL
|
Canada | CA$429.54 Million |
|
eQ Oyj
HE:EQV1V
|
Finland | €18.67 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Eupraxia Pharmaceuticals Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see EPRX total asset value.
Liquidity & Leverage Metrics
Eupraxia Pharmaceuticals Inc. Common Stock Total Liabilities Ratios Explained
Eupraxia Pharmaceuticals Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 23.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eupraxia Pharmaceuticals Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eupraxia Pharmaceuticals Inc. Common Stock (2017–2024)
The table below shows the annual total liabilities of Eupraxia Pharmaceuticals Inc. Common Stock from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.10 Million | -83.98% |
| 2023-12-31 | $19.37 Million | +20.10% |
| 2022-12-31 | $16.13 Million | +33.27% |
| 2021-12-31 | $12.10 Million | -47.64% |
| 2020-12-31 | $23.12 Million | +7.94% |
| 2019-12-31 | $21.42 Million | +49.30% |
| 2018-12-31 | $14.34 Million | +1849.47% |
| 2017-12-31 | $735.82K | -- |
About Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unm… Read more